| Literature DB >> 32481314 |
Dandan Li1, Cheng Wang, Di Ruan, Jingjing Li, Ning Ji, Xinwen Ma, Yongtao Li, Yujiang Qu, Zhijin Xuan, Lihua Song.
Abstract
To study the effects of Tui Na therapy on patients with mammary gland hyperplasia.A total of 68 female patients with mammary gland hyperplasia were included in this retrospective study from May 2016 to May 2017 and assigned into control group (N = 34) treated with Rupixiao only (a proprietary Chinese medicine) or Tui Na group (N = 34) treated with Tui Na (Chinese massage) combined with Rupixiao. The pain intensity (visual analogous scale, VAS) and serum levels of luteinizing hormone (LH), estradiol (E2), prolactin (PRL), and progesterone (P) were examined before and after the treatment.The efficacies were 94.1% (32/34) in the Tui Na group and 76.5% (26/34) in the control group (P = .04). After treatment, VAS in Tui Na groups was significantly lower than that in control group (2.1 ± 1.1 vs 3.1 ± 1.1, P < .05). After follow-up for five months, the recurrence rates were 12.5% (4/32) in the Tui Na group and 23.1% (6/26) in the control group (P = .01). The levels of all 4 hormones in the Tui Na group increased significantly after treatment. In control group, only LH and E2 levels were significantly increased after treatment.In patients with mammary gland hyperplasia, Tui Na combined with Rupixiao could improve clinical symptoms, regulate sex hormone levels, and decrease the recurrence rate than Rupixiao alone. Our finding suggests that Tui Na can be potentially used for the treatment of mammary gland hyperplasia.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32481314 PMCID: PMC7249953 DOI: 10.1097/MD.0000000000020300
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Baseline characteristic of patients in Tui Na and control groups (N = 68).
Figure 1Patient enrollment flowchart (E2 = estradiol, LH = luteinizing hormone, PRL = prolactin, P = progesterone, VAS = visual analogous scale).
Outcome of patients in Tui Na and control groups (N = 68).
Figure 2Secondary outcomes in the Tui Na and the control groups (E2 = estradiol, LH = luteinizing hormone, PRL = prolactin, P = progesterone, VAS = visual analogous scale). ∗, P < .01 when comparing the Tui Na group with the control group in the post-treatment period.